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GVHD IN MULTI-VISCERAL TRANSPLANT RECIPIENTS
Shin, C.R.1, Filopovich, A.L.1, Yazigi, N.2, Bucuvalas, J.2, Campbell, K.2,
Tiao, G.3, Alonso, M.2, Bleesing, J.1, Davies, S.1 1Cincinnati Children’s
Hospital Medical Center, OH; 2Cincinnati Children’s Hospital Medical
Center, OH; 3Cincinnati Children’s Hospital Medical Center, OH
Introduction: GVHD is a rare but life-threatening complication
following solid organ transplant with high (.50%) mortality.
Transfer of imunologically competent cells into an immunosup-
pressed host during solid organ transplantation results in detect-
able levels of donor T cell chimerism in recipient peripheral
blood. During multi-visceral transplantation, lymphocytes are
transferred with the graft into an immunocompromised host in
the setting of minimal HLA matching. This scenario of active do-
nor lymphocytes in an immune compromised host in the setting of
HLA mismatch at all or most loci facilitates the development of
GVHD.
Hypothesis: We hypothesize that a small level of donor T cell chi-
merism (0-5%) will increase recipient tolerance of the donor graft
and increased donor T cell chimerism (.15%) will increase the in-
cidence and severity of GVHD following solid organ transplanta-
tion.
Methods:Data from all children treated with multi-visceral trans-
plantation at Cincinnati Children’s Hospital Medical Center from
2003 to 2009 were analyzed retrospectively to identify the fre-
quency of donor T-cell chimerism, and the frequency of clinical
GVHD. Demographic data, transplant characteristics, donor char-
acteristics, and donor T cell chimerism, and GVHD were ana-
lyzed.
Results: A total of 32 patients were included in the study. Median
age at time of transplantation was 2.62 years. The incidence of
GVHD was 19% (6 of 32 patients). Grade I-II GVHD was ob-
served in 4 patients and grade III-IV GVHD was observed in 2 pa-
tients. All patients with GVHD demonstrated skin involvement. A
total of 11 patients had donor T cell chimerism data available. Do-
nor T cell chimerism was low (0-5%) in 18%, moderate (5-15%) in
9%, and high (.15%) in 73% of patients. 100% of patients with
GVHD had detectable levels of donor T cells. Increased (.15%)
donor T cell chimerism was noted in 5 of 6 (83%, p\0.05) pa-
tients with GVHD following multivisceral transplantation. Three
of six (50%) patients with GVHD are surviving after treatment
with immune suppression.
Conclusions: Patients with moderate to increased levels of donor T
cell chimerism are at increased risk of developing GVHD following
transplantation of lymphocyte rich solid organs. Patients who de-
velop GVHD commonly have skin manifestations. Patients with
a new rash following solid organ transplant with detectable levels
of donor T cell chimerism should receive a skin biopsy to evaluate
for GVHD.432
INDUCED STERILE SEROSAL EFFUSION BY ACUTE GVHD AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Dias, J.B.E.1, Barros, G.M.N.1, Stracieri, A.P.1, Rodrigues, M.C.1,
Moraes, D.A.1, Cle Darrigo, D.V.1, Jr, L.G.1, Cunha, R.G.1,
Simo˜es, B.2, Voltarelli, J.C.2, Pieroni, F.1 1Clinical Hospital, Ribeira˜o
Preto, Sa˜o Paulo, Brazil; 2School of Medicine of Ribeira˜o Preto-University
of Sa˜o Paulo, Brazil
Sterile serosal effusion after allo-HSCT has been described, but
it is still a poorly characterized entity. We describe a case of mas-
sive pleural effusion in a 10 years old male that was submitted to
an identical sibling allo-PBHSCT for acute biphenotype leukemia.
The conditioning was the BuCyMel. He received 12,9106
CD34+ cells/kg. The GVHD prophylaxis was CSA and MTX.
On D + 17, the patient developed moderated cutaneous and intes-
tinal aGVHD treated with high dose steroid for 6 weeks with
complete response to therapy. On D + 59, he developed positive
antigenemia for CMV without any signs of disease. He was treated
with gancyclovir for 4 weeks until the steroid was tapered. He be-
came antigenemia negative since the second week of treatment.
On D + 65, he was diagnosed with hemorrhagic cystitis and apositive PCR for polyomavirus was detected on blood and urine.
Cydofovir was initiated to treat him. On D + 69, he related dysp-
neia and a massive bilateral pleural effusion was detected by chest
 ray. He didn’t show any other symptoms of GVHD at this time.
The echo showed a mild pericardial effusion with 62% ejection
fraction and the ultrasound of the abdomen showed a moderated
ascites. The renal function and albumin were normal, proteinuria
and antinucleolar antibody were negative. He was submitted to
a bilateral pleural drainage with pleural and lung biopsy that
showed thickening of the conjunctive tissue of the pleura, and
rare macrophages and/or endothelial cells with a high hyperchro-
matic nuclei suggestive of cytopathic viral action in the lung. The
IMF and PCR analyses were negative for CMV and polyomavirus
in the tissues biopsies and in the transudate pleural effusion. Since
the patient was already in use of cydofovir without improvement
of the drainaged effusions, we decided to restart with prednisone
2 mg/kg/d. The patient presented with prompt clinical response
after steroids and became free of drainage on D + 91. In this
case, we don’t know if the effusions were caused by CMV or poly-
oma, since these virus were negative in the biopsies and effusions.
Moreover, we can’t exclude that these effusions were not a manifes-
tation of acute GVHD triggered by the presence of CMV or poly-
oma infections, since the patient had an optimal response to
steroids. In conclusion: recently, some cases of serosal effusions
have been related to acute GVHD. However, this relationship
needs to be more studied to be associated definitively to acute
GVHD, viral infections or both.433
STEROID-SENSITIVE UPPER ACUTE GASTROINTESTINAL ACUTE GRAFT-
VERSUS-HOSTDISEASEDIAGNOSEDWITHOUTTHEHISTOPATHOLOGICAL
FINDING
Mori, M., Muroi, K., Matsuyama, T., Fujiwara, S., Ozawa, K. Jichi
Medical University Hospital, Shimotsuke, Tochigi, Japan
Introduction: The gastrointestinal (GI) tract is the major target site
of the acute graft-versus-host disease (aGVHD), however, it and the
degree of severity in which is not diagnosed with easy.
Patients andMethods: Sixty-seven patients (pts) with HSCT in our
center from 2006 to 2009 were evaluated. Among them, 34 acute my-
elogenous leukemia, 9 acute lymphoblastic leukemia, 2 chronic my-
elogenous leukemia, 11 myelodysplastic syndrome, and 11
malignant lymphoma were diagnosed. Eight peripheral bloods, 50
bone marrows and 10 cord bloods were transplanted from 14 related
donors and 54 unrelated donors with the conditioning treatments,
including 52 myeloablative and 15 non-myeloablative regimens.
The numbers of HLA-mismatch locus were serologically 8 at 4/6
or less than, 8 at 5/6, and genetically 13 at 4/6 or less than and 16
at 5/6. GVHD prophylaxis included FK506 plus short-term metho-
trexate (sMTX) for 53 pts and cyclosporine plus sMTX for 14 pts.
When nausea and vomiting started after the weakness of regimen-re-
lated toxicities, the endoscopic finding and the biopsy were operated.
As soon as possible, steroid at a dose of 1.0 mg/kg per day firstly
was administered for the treatment of upper GI-aGVHD at the point
of clinical diagnosis of it.
Results: Seven patients were applicable, but they had notable fea-
tures in their background. Four of them had stage 1 lower GI-
aGVHD and 4 of them complicated with stage 1 to 2 skin
aGVHD, therefore the final grades of their aGVHD were from
0 to 2, not seriously. The symptoms started at the mean of 19.4
(13-26) days after HSCT, and the endoscopic finding and the treat-
ment was administered at the mean of 26.3 (21-35) days and 28.0
(21-34) days after the symptoms. Due to a clinical observation,
each of the diagnosis and the treatment to upper GI-aGVHD
were delayed for 5.8 days and 8.6 days. All of 6 patients examined
with the gastric biopsy were not histopathologically confirmed, but
interestingly, five among of them except for one at the non-remis-
sion state were quickly recovering. There were not pts with relapse
after the steroid-therapy.
Conclusion: We consider that the diagnosis of upper GI-aGVHD
based on the histopathological finding is in part difficult, but the re-
sponse to the treatment with steroid in mostly is sensitive and safety.
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ALLOGENEIC IMMUNOTHERAPY: AN EFFECTIVE TREATMENT FOR LUNG
CANCER
Brandon, J.A.1,4, Jennings, C.D.2,4, Cohen, D.3,4, Kaplan, A.M.3,4,
Bryson, J.S.1,3,4 1University of Kentucky, Lexington, KY; 2University of
Kentucky, Lexington, KY; 3University of Kentucky, Lexington, KY; 4Uni-
versity of Kentucky, Lexington, KY
Therapeutic strategies for non-small cell lung carcinoma
(NSCLC) include surgery, chemotherapy and radiation. Many
NSCLC patients present with advanced disease that is not treatable
by surgery or does not respond to chemotherapy or radiation treat-
ment. An alternative therapeutic approach is the use of allogeneic
hematopoietic stem cell transplantation (HSCT) that utilizes the
responsiveness of a donor T lymphocyte graft to respond against
histocompatibility antigens present on lung cancer cells. It has
been shown that a beneficial graft-versus-tumor (GVT) response
is associated with a major complication of HSCT, graft-versus-
host disease (GVHD). Allogeneic HSCT has been utilized to treat
a number of hematologic malignancies and recently selected epi-
thelial solid tumors. The use of this procedure resulted in regres-
sion of renal cell carcinoma lung metastases and a case report
demonstrated the elimination of NSCLC following HSCT. Given
these findings, we utilized major histocompatibility antigen mis-
matched murine bone marrow transplantation (BMT) models and
bioluminescence imaging to test the hypothesis that the allogeneic
immune response that develops following allogeneic HSCT will be
effective in controlling growth of lung cancer. Our results demon-
strated that while GVHD did not develop following reduced inten-
sity (RIC) conditioning and allogeneic donor lymphocyte infusion
(DLI) 28 days after BMT, DLI failed to limit the growth of lung
tumors. In contrast, when DLI was given after lethal myeloablative
conditioning and BMT, a significant reduction in lung tumor
growth was observed in the absence of GVHD. In line with a reduc-
tion in tumor growth, trafficking studies demonstrated that alloge-
neic donor cells migrated at an increased frequency to the lungs of
myeloablated recipients compared to those conditioned with the
RIC regimen. These studies demonstrate the potential efficacy of
allogeneic immunotherapy and provide a model system to study al-
ternative therapeutic options in the treatment of malignancies of
the lung.Gas Exchange Outcomes in Criticall Ill Stem Cell Transplant
Recipients who Received Nebulized Dornase Alfa
Mean
PF ratio
95% CI
(p-value vs
baseline)
Mean
FiO2
95% CI
(p-value vs
baseline)
Baseline 235.8 147.5 - 324.0 0.54 0.33 - 0.76
24 hour 252.8 166.5 - 339.1
(p5 0.6461)
0.53 0.36 - 0.71
(p5 0.9060)
48 hour 251.9 165.9 - 338.9
(p5 0.6725)
0.45 0.34 - 0.56
(p5 0.2610)435
GVHD FOLLOWED BY FULL MYELOID AND LYMPHOID DONOR CHIME-
RISM AFTER CADAVERIC LIVER TRANSPLANTATION
Malone, A.K.1, Gudzowaty, O.2, Grosskreutz, C.1, Scigliano, E.1,
Osman, K.1, Choo, Y.2, Isola, L.1 1Mount Sinai School of Medicine,
New York, NY; 2Mount Sinai School of Medicine, New York, NY
Introduction:Using hematopoietic donor engraftment as a way to
establish immune tolerance in solid organ transplantation remains
an attractive but elusive goal. We report a case of orthotopic liver
transplantation (OLT)-related aGVHD followed by full chime-
rism of highly HLA-mismatched myeloid and lymphoid donor
cells.
Case report: A 58-year old male with HCV cirrhosis underwent
OLT from a sex and blood type matched (O+) deceased donor.
HLA typing of the donor and recipient demonstrated only one
shared antigen on DRB1. On post-op day (POD) 42, profound pan-
cytopenia developed. BM Bx showed aplastic anemia. On POD 62,
the patient developed grade III skin aGVHD. Methylprednisolone
(1 mg/kg) was added to tacrolimus. Infliximab (10 mg/kg) was given
on POD 81 and 88. The rash and blood counts gradually improved.
Immunosuppression and hematopoietic growth factors were tapered
and blood and transfusion requirements decreased substantially.
Molecular-based HLA typing of PB nucleated cells on POD 71
showed a major population of donor cells. VNTR/STR chimerism
analysis at the D1S80 locus showed 100% donor type in BM
(POD 98) and PB CD3+ and CD33+ compartments (POD 103).Skin GVHD resolved and counts remained stable with modest
growth factor support and periodic transfusion of red cells and plate-
lets.
Discussion: GHVD occurs in approximately 1% of OLT’s and is
a life-threatening complication. It is mediated by passenger lym-
phocytes across major HLA barriers and facilitated by permissive
antigen sharing between donor and recipient. While donor chime-
rism of lymphoid cells is often seen in these cases, full hematopoi-
etic engraftment has only been documented once. Our patient and
donor shared a single class II HLA antigen. After complete sup-
pression of host hematopoiesis, sustained donor lymphoid and my-
eloid engraftment occurred with minimal immunosuppression.
This observation suggests the emergence of immune tolerance in
the graft-versus-host direction across HLA barriers beyond a full
haplotype. It also demonstrates the existence of hematopoietic
progenitors in a liver graft capable of reconstituting in an adult
patient.PHARMACY
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EFFECT OF NEBULIZED DORNASE ALFA ON PULMONARY GAS EXCHANGE
IN CRITICALLY ILL STEM CELL TRANSPLANT RECIPIENTS
Dee, B.M.1, Lal, L.S.1, Pravinkumar, S.E.2 1UTM.D. Anderson Cancer
Center, Houston, TX; 2UT M.D. Anderson Cancer Center, Houston, TX
Introduction: Dornase alfa (DA), a recombinant human deoxyribo-
nuclease, is used in non-cystic fibrosis patients primarily for its mu-
colytic properties. The objective of this study was to examine the
effect of DA on gas exchange in critically ill adult cancer patients
with tenacious pulmonary secretions or atelectasis.
Methods: Following IRB approval, medical records of ICU pa-
tients who received nebulized DA for. 72 hrs between 1/1/05
and 10/1/08 were retrospectively studied, including a subset anal-
ysis of stem cell transplant (SCT) patients. The PaO2, FiO2, and
PaO2/FiO2 (PF) ratio at baseline, 24 hrs, and 48 hrs post-DA ad-
ministration were analyzed using the paired t-test and the Wil-
coxon sign rank test. P-values\0.05 were considered
statistically significant, while an improvement in PF ratio by
50% or to a value of 100 above baseline were considered clinically
significant.
Results:During the six-month study period, 109 critically-ill adult
patients underwent treatment with DA, of which 9 (8%) were SCT
recipients. Six patients received allogeneic transplants and 3 re-
ceived autologous transplants. Sixty-seven percent of SCT recipi-
ents had radiographic evidence of pulmonary infiltrates and 33%
had pulmonary collapse. All nine patients were mechanically ven-
tilated. No statistically significant results were observed in SCT
recipients with regards to change in PF ratio or FiO2 from base-
line to 24 or 48 hrs (see Table). The PF ratio increased by 50%
above baseline in 22.2% and 33.3% of SCT recipients at 24 hrs
and 48 hrs, respectively. The PF ratio increased to a value of
100 above baseline in one SCT recipient (11.1%) at 24 hrs and
48 hrs.
Conclusion:No statistically or clinically significant pulmonary gas ex-
change benefits were seen in SCT recipients who were treated with DA
when used as a mucolytic agent. Further research is needed to establish
if DA may be a viable treatment option in critically ill adult SCT
patients.
